2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.
Craig Sauter, MD, director, Blood and Marrow Transplant Program, Hematology and Medical Oncology, Cleveland Clinic, discusses the investigation of pembrolizumab (Keytruda) given after stem cell transplant in T-cell non-Hodgkin lymphoma (NHL).
There is evidence for single-agent PD-1 inhibition in subtypes of peripheral T-cell lymphoma(PTCL), Sauter says. Additionally, high-dose chemotherapy followed by stem cell transplant can provide a unique opportunity to administer immunotherapy in a lymphodepleted environment, Sauter explains.
Because of their rarity, investigators examined this approach in a small cohort of 21 patients with various PTCL histologies, Sauter continues. The primary end point of the investigation was met within this cohort with 62% of the patients being progression free at 18 months, Sauter explains. In the future, it will be important to delineate which histologies are particularly sensitive to this intervention, Sauter concludes.
Related Content: